VCEL  valuation analysis

Name: Vericel Corporation
Description: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 04, 2022
Market cap: $1.27B (1165th)
Sales(TTM): $157.69M (1382nd)
Earnings(TTM): -$11.27M (1264th)

FFER: 2.96*
Actual price: $26.93
* Earnings were reported Aug 02, 2022 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2022-05-25
Price & Estimates
Sales & Earnings history (TTM)
  • Vericel Corporation's earnings decreased from $4.28M to -$11.27M in the last year.
  • Vericel Corporation's operating income decreased from $4.14M to -$11.82M in the last year.
Earnings / MarketCap
Vericel Corporation
"Biotechnology" industry
Sales / MarketCap
Vericel Corporation
"Biotechnology" industry
Book / MarketCap
Vericel Corporation
"Biotechnology" industry
Equity / Assets
Vericel Corporation
"Biotechnology" industry